The company has strengthened its partnership with the Havana-based Centre of Molecular Immunology (CIM) by joining forces for an integrated anti-body programme in immunology, Biocon said in a statement.
The parties are now looking to create an innovative product pipeline focused on auto-immune diseases and cancer and have identified an anti-body, ‘Anti-CD6’, which targets lymphocytes, the key players in the immuno-pathology of a auto-immune disease, it added.